ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / ANVS / insiders
HOWL (42) SER (31) GANX (41) IBIO (23) ⌘ Pro Terminal β†’

Annovis Bio Inc. (ANVS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.08 -4.42% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.07

Annovis Bio Inc. (ANVS) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- β€’ RED ALERT Cap $48.2M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANVS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ANVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Annovis Bio Inc. (NYSE: ANVS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.08 (-4.42% 1D, market cap $48.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ANVS ranks #601 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ANVS compare to HOWL and SER in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANVS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, HOWL (Werewolf Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $47.9M) and SER (Serina Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M). Among the 5-stock peer group, ANVS leads on earnings multiple (N/A) while ANVS leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANVS?
β–Ό

Per ANVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001477845), Annovis Bio Inc. generated $83.1M in revenue (+11.2% YoY), -$28.9M in net income, and -$25.6M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.07 (-0.99%)🧬 Disciplined Float (+0.72% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (35/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510035
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk D
Cash (7)Whales (5)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.2% Base Target
$6 Bull$1 Base$1 Bear
πŸ“¬ FREE ANVS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ANVS)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (35/100 Composite)
πŸ” WHY ANVS SCORES 35/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 1/9

β–² #2 Bullish Driver: Macro Regime Fit+8/20 pts (23% of score)

FRED Regime Γ— Technicals: 3% of 52W Range β€’ RSI-14 at 51.7 (NEUTRAL RANGE)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
27
Grade E$1.06-7.5% Next Q
Q2 (-2Q)
30
Grade E$0.98+2% Next Q
Q3 (-1Q)
32
Grade E$1.00+8% Next Q
Current
35
Grade D-$1.08-8.5% Hist 90D Ξ±
Trajectory: E (27) β†’ D- (35)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ANVS Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ANVS currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($1.13) forces dealer call-delta covering toward $5.78.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANVSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œANVS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 35%NO 65%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

ANVS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ANVS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ANVS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANVS)

  • βœ“Walkthrough of ANVS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ANVS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.63%β–Ό DESCENDING CHANNEL
2026-11-03O $1.02H $1.13L $1.02C $1.08VOL 1.50M
RES: $1.53SUP: $0.70SMA50: $1.23SMA200: $1.90
$2.78$2.28$1.78$1.28$0.77RES $1.53SUP $0.70$1.082026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANVS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ANVS Butterfly Map β†’ + Track ANVS β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +11.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ANVS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ANVS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANVS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANVS)

Health Care Rank #601 of 1015 βš”οΈ HOWL vs ANVS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ANVS vs. HOWL, SER, GANX, IBIO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Annovis Bio Inc. (ANVS) ranks #601 by composite RQD confidence (35/100, grade D-) and #751 by equity capitalization ($48.2M). Within this direct 5-issuer industry benchmark cohort, ANVS leads on earnings valuation at N/A trailing P/E, while ANVS leads on capital efficiency and profitability with -35.0% ROIC and β€” gross margin. HOWL currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with ANVS at 35/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ANVS ACTIVE
Annovis Bio Inc.
D- 35/100 β€” β€” -35.0% -4.42% $48.2M Benchmark Subject
HOWL
Werewolf Therapeutics Inc.
D- 42/100 β€” β€” -35.0% +6.48% $47.9M /howl-vs-anvs β†’
SER
Serina Therapeutics Inc.
E 31/100 β€” β€” -35.0% -4.64% $49.3M /ser-vs-anvs β†’
GANX
Gain Therapeutics Inc.
D- 41/100 β€” β€” -35.0% 0.00% $49.3M /ganx-vs-anvs β†’
IBIO
iBio Inc.
E 23/100 β€” β€” -35.0% +4.06% $49.4M /ibio-vs-anvs β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001477845 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Annovis Bio Inc. (ANVS) reported GAAP revenue of $83.1M (+11.2% vs. FY2024 revenue of $74.7M , and -34.1% cumulative change since FY2023) , GAAP net income of -$28.9M, operating cash flow of -$25.6M, and free cash flow of -$25.6M (-17.0% YoY). On the balance sheet, ANVS closed FY2025 with $21.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $83.1M -$28.9M -$25.6M -$25.6M $21.1M β€”
FY2024 (FY) 2024-12-31 $74.7M -$24.6M -$21.9M -$21.9M $13.9M β€”
FY2023 (FY) 2023-12-31 $126.1M -$56.2M -$40.0M -$40.0M β€” β€”

3. ANVS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANVS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Annovis Bio Inc. (NYSE: ANVS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.08 (-4.42% 1D, market cap $48.2M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ANVS ranks #601 in composite RQD confidence.

How does ANVS compare to HOWL and SER in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANVS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of β€”, and ROIC of -35.0%. By comparison, HOWL (Werewolf Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $47.9M) and SER (Serina Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $49.3M). Among the 5-stock peer group, ANVS leads on earnings multiple (N/A) while ANVS leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANVS?

Per ANVS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001477845), Annovis Bio Inc. generated $83.1M in revenue (+11.2% YoY), -$28.9M in net income, and -$25.6M in free cash flow against $21.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANVS trading relative to its 50-day, 200-day, and 52-week technical levels?

ANVS last traded at $1.08 (-4.42% on volume of 3,011,634 shares), positioning the stock -12.20% below its 50-day simple moving average ($1.23) and -43.16% below its 200-day simple moving average ($1.90). Across its 52-week range of $0.93 to $5.50, ANVS sits at the 3.3% percentile with a 14-day RSI of 51.7 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.00 to $1.22).

Direct Sub-Reports: ANVS RQD Cockpit ANVS 12M Forecast ANVS Earnings & Move ANVS Dividends & DRIP ANVS Insiders & 13F ANVS Whale Options ANVS Profit Sankey ANVS News & Why
ROARABLE RATING BRIEF β€’ RQD 35/100 (D-) βœ“ SEC XBRL & RQD VERIFIED

ANVS β€” Annovis Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Annovis Bio Inc. (ANVS) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.08 (-4.42% 1D, market capitalization $48.2M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of β€”, operating margin of β€”, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Annovis Bio Inc. Is a NYSE-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The issuer's market capitalization is $0.0B. β€” for product detail, customer base, or revenue model beyond the reported revenue of β€” across FY 2023–FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Annovis Bio Inc. (ANVS) reported $83.1M in annual revenue (up from $74.7M in FY2024, +11.2% YoY) and -$28.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($126.1M revenue, -$56.2M net income) through FY2025, ANVS scaled operating cash flow to -$25.6M and free cash flow to -$25.6M, backed by $21.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D- β€’ RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $0.93 – $5.50 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against β€” operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ANVS carries a macro regime beta of 1.00 and gross margin of β€”.

  • Key Question #1: Can ANVS sustain or expand its β€” operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $83.1M and free cash flow of -$25.6M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ANVS's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ANVS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Annovis Bio Inc. (ANVS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ANVS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANVS Bull vs. Bear Conversation Board β€” What's Your Call at $1.08?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANVS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ANVS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER β€’ Options Flow Specialist πŸ‚ BULLISH 🎯 Target: $1.31 (+15.9%)
πŸ“Œ Pinned Debate

Cash rose to $19.5M in FY 2025 from $10.6M in FY 2024, and the RQD rating shows a beta of 1.0 with an Altman Z-Score of 2.5.

Picked up a starter position in ANVS in my $100K Virtual Cash book at $1.13. Cash rose to $19.5M in FY 2025 from $10.6M in FY 2024, and the RQD rating shows a beta of 1.0 with an Altman Z-Score of 2.5.. Trading inside a $0.93–$5.50 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

EarningsSniper πŸ‚ BULL

@BearTrap_Alert Shorting a 5/20 institutional whale-flow stock at $1.13 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER β€’ Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $0.85 (-24.8%)
Spot @ $1.13

The RQD rating scores 33 with an E grade, ROIC is -35%, FCF yield is 0%, and FY 2025 FCF was -$25.6M against a $0.0M revenue base.

Careful chasing ANVS at $1.13. The RQD rating scores 33 with an E grade, ROIC is -35%, FCF yield is 0%, and FY 2025 FCF was -$25.6M against a $0.0M revenue base.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.85 on multiple compression.

LIVE TAPE